Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.
(
ITN091AI
|
VIBRANT
)
Principal Investigator:
Maria Dall'era | University of California San Francisco | San Francisco, CA
Betty Diamond | The Feinstein Institute for Medical Research | Manhasset, NY
David Wofsy | University of California San Francisco | San Francisco, CA
The goal of the VIBRANT trial is to determine if treating lupus nephritis with VIB4920 in addition to standard therapy is more effective than treating lupus nephritis with standard therapy alone.
Category:
Autoimmune Disease
|
Specific Category:
Lupus Nephritis
|
Status:
Enrollment
Learn more:
(
ITN090ST
|
ATTAIN
)
Principal Investigator:
Flavio Vincenti | University of California San Francisco | San Francisco, CA
Rajalingam Raja | University of California San Francisco | San Francisco, CA
The goal of ATTAIN is to study whether using two drugs, daratumumab and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Enrollment
Learn more:
(
ITN089ST
|
ADAPT
)
Principal Investigator:
Stuart Knechtle | Duke University School of Medicine | Durham, NC
The goal of the ADAPT study is to study whether using two drugs, carfilzomib and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Enrollment
Learn more:
(
ITN086AI
|
REVEAL
)
Principal Investigator:
Brett King | Yale School of Medicine | Middlebury, CT
The REVEAL study will investigate whether the experimental study medication, AMG714, can bring back normal color to the skin in vitiligo.
Category:
Autoimmune Disease
|
Specific Category:
Vitiligo
|
Status:
Follow-up
Learn more:
(
ITN084AD
|
GRADUATE
)
Principal Investigator:
Stephen Durham | Imperial College London | London, England
GRADUATE is a clinical research trial, which will test whether a novel drug called Dupixent® given with grass pollen immunotherapy will help the immunotherapy work in a shorter treatment period and remain effective after the completion of treatment.
Category:
Allergy & Asthma
|
Specific Category:
Grass Allergy
|
Status:
Follow-up
Learn more:
(
ITN080AI
|
REBOOT
)
Principal Investigator:
Patrick Nachman | University of Minnesota | Minneapolis, MN
REBOOT will test whether a combination of, belimumab and rituximab, is safe and if this combination is more effective at blocking the immune attack on the kidney of patients with Primary Membranous Neuropathy (MN).
Category:
Autoimmune Disease
|
Specific Category:
Autoimmune Diseases
|
Status:
Enrollment
Learn more:
(
ITN079AD
|
ACTIVATE
)
Principal Investigator:
Hugh Sampson | Mount Sinai Hospital | New York, NY
Jose C. Clemente | Icahn Institute for Genomics & Multiscale Biology | New York, NY
ACTIVATE is a clinical trial investigating the impact of the infant microbiome on allergy development.
Category:
Allergy & Asthma
|
Specific Category:
Food Allergy
|
Status:
Follow-up
Learn more:
Principal Investigator:
Jeffrey Cohen | Cleveland Clinic | Cleveland, OH
Paolo Muraro | Imperial College London | London,
George Georges | Fred Hutchinson Cancer Research Center | Chicago, IL
BEAT-MS is a clinical trial comparing chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) – a type of bone marrow transplantation – to the most effective medicines regularly used to treat relapsing MS.
Category:
Autoimmune Disease
|
Specific Category:
Multiple Sclerosis
|
Status:
Enrollment
Learn more:
(
ITN075AI
|
BRAVOS
)
Principal Investigator:
Dinesh Khanna | University of Michigan | Ann Arbor, MI
David Fox | University of Michigan | Ann Arbor, MI
BRAVOS is a clinical trial evaluating Brentuximab Vendotin treatment for Diffuse Cutaneous Systemic Sclerosis.
Category:
Autoimmune Disease
|
Specific Category:
Scleroderma
|
Status:
Analysis
Learn more:
(
ITN073ST
|
LITTMUS_MGH
)
Principal Investigator:
James Markmann | Massachusetts General Hospital | Philadelphia, PA
Eva Guinan | | Boston, MA
LITTMUS is a clinical research study testing a new approach to achieve transplant tolerance using the liver transplant recipient’s own T regulatory cells (Tregs).
Category:
Transplantation
|
Specific Category:
Liver Transplantation
|
Status:
Follow-up
Learn more:
No items found.